For the Rest

Johnson & Johnson bid 1.75 billion euros to buy the rest of the Dutch biotechnology company Crucell, reports The New York Times' DealBook, which notes that Johnson & Johnson already owns nearly 18 percent of the biotech. The offer for the company, which specializes in vaccines and therapeutics for infectious diseases, is 24.75 euros a share, and is supported by the Crucell board. The bid goes to a vote in early February.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor among brittle stars, single-cell RNA sequencing strategy, and more.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.